Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor requires e-cadherin in esophageal cancer and malignant pleural mesothelioma

Anticancer Research

Volumn 33, Issue 6, 2013, Pages 2401-2408

  Xin, Hong Wu ^a   Yang, Jian Hui ^a,b   Nguyen, Dao M ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Pharmacy Department of Peking University People s Hospital   (China)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

E Cadherin; Epidermal growth factor receptor; Epithelial to mesenchymal transition (EMT); Esophageal cancer; Malignant pleural mesothelioma; Tyrosine kinase inhibitor

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; UVOMORULIN; 4 ((3 BROMOPHENYL)AMINO) 6,7 DIMETHOXYQUINAZOLINE; 4-((3-BROMOPHENYL)AMINO)-6,7-DIMETHOXYQUINAZOLINE; CADHERIN; ENZYME INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER RESISTANCE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGUS CANCER; HUMAN; HUMAN CELL; MARKER GENE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; E-CADHERIN; EPITHELIAL TO MESENCHYMAL TRANSITION (EMT); ESOPHAGUS TUMOR; GENE EXPRESSION REGULATION; GENETICS; LUNG TUMOR; MESOTHELIOMA; METABOLISM; TUMOR CELL LINE;

E-CADHERIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL TO MESENCHYMAL TRANSITION (EMT); ESOPHAGEAL CANCER; MALIGNANT PLEURAL MESOTHELIOMA; TYROSINE KINASE INHIBITOR;

CADHERINS; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; EPITHELIAL-MESENCHYMAL TRANSITION; ESOPHAGEAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84881414123     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Agarwal V, Lind MJ and Cawkwell L: Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand? Cancer treatment reviews 37: 533-542, 2010.
2. Anders M, Christian C, McMahon M, McCormick F and Korn WM: Inhibition of the Raf/MEK/ERK pathway up-regulates expression of the coxsackievirus and adenovirus receptor in cancer cells. Cancer Res 63: 2088-2095, 2003.
3. Baselga J and Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23: 2445-2459, 2005.
4. Black PC, Brown GA, Inamoto T, Shrader M, Arora A, Siefker-Radtke AO, Adam L, Theodorescu D, Wu X, Munsell MF, Bar-Eli M, McConkey DJ and Dinney CP: Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clinical cancer research 14: 1478-1486, 2008.
5. Bos M, Mendelsohn J, Kim YM, Albanell J, Fry DW and Baselga J: PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin Cancer Res 3: 2099-2106, 1997.
6. Buck E, Eyzaguirre A, Barr S, Thompson S, Sennello R, Young D, Iwata KK, Gibson NW, Cagnoni P and Haley JD: Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther 6: 532-541, 2007.
7. Christiansen JJ and Rajasekaran AK: Reassessing epithelial to mesenchymal transition as a prerequisite for carcinoma invasion and metastasis. Cancer Res 66: 8319-8326, 2006.
8. Cohen MH, Johnson JR, Chen YF, Sridhara R, and Pazdur R: FDA drug approval summary: erlotinib (Tarceva) tablets. The oncologist 10: 461-466, 2005.
9. Cole GW Jr., Alleva AM, Reddy RM, Maxhimer JB, Zuo J, Schrump DS, and Nguyen DM: The selective epidermal growth factor receptor tyrosine kinase inhibitor PD153035 suppresses expression of prometastasis phenotypes in malignant pleural mesothelioma cells in vitro. The Journal of thoracic and cardiovascular surgery 129: 1010-1017, 2005.
10. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, Connors RW and Bridges AJ: A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science (New York, NY 265: 1093-1095, 1994.
11. Jin Z, Cheng Y, Olaru A, Kan T, Yang J, Paun B, Ito T, Hamilton JP, David S, Agarwal R, Selaru FM, Sato F, Abraham JM, Beer DG, Mori Y, Shimada Y and Meltzer SJ: Promoter hypermethylation of CDH13 is a common, early event in human esophageal adenocarcinogenesis and correlates with clinical risk factors. International journal of cancer 123: 2331-2336, 2008.
12. Ku GY and Ilson DH: Esophagogastric cancer: targeted agents. Cancer treatment reviews 36: 235-248, 2010.
13. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
14. Nam JS, Ino Y, Sakamoto M and Hirohashi S: Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis. Clin Cancer Res 8: 2430-2436, 2002.
15. Nguyen DM and Schrump DS: Growth factor receptors as targets for lung cancer therapy. Seminars in thoracic and cardiovascular surgery 16: 3-12, 2004.
16. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. New York, NY 304: 1497-1500, 2004.
17. Petrelli F, Borgonovo K, Cabiddu M and Barni S: Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-Analysis of 13 randomized trials. Clinical Lung Cancer 13: 107-114, 2012.
18. Qian X, Karpova T, Sheppard AM, McNally J and Lowy DR: Ecadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. The EMBO J 23: 1739-1748, 2004.
19. Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM and Figlin RA: A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clin Cancer Res 12: 3381-3388, 2006.
20. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P and Seymour L: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132, 2005.
21. Sutter AP, Hopfner M, Huether A, Maaser K and Scherubl H: Targeting the epidermal growth factor receptor by erlotinib (Tarceva) for the treatment of esophageal cancer. International journal of cancer 118: 1814-1822, 2006.
22. Thomson S, Buck E, Petti F, Griffin G, Brown E, Ramnarine N, Iwata KK, Gibson N and Haley JD: Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer research 65: 9455-9462, 2005.
23. Witta SE, Gemmill RM, Hirsch FR, Coldren CD, Hedman K, Ravdel L, Helfrich B, Dziadziuszko R, Chan DC, Sugita M, Chan Z, Baron A, Franklin W, Drabkin HA, Girard L, Gazdar AF, Minna JD and Bunn PA Jr.: Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer research 66: 944-950, 2006.
24. Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, Modrusan Z, Lin CY, O'Neill V and Amler LC: Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11: 8686-8698, 2005.
25. Yeow WS, Ziauddin MF, Maxhimer JB, Shamimi-Noori S, Baras A, Chua A, Schrump DS and Nguyen DM: Potentiation of the anticancer effect of valproic acid, an antiepileptic agent with histone deacetylase inhibitory activity, by the kinase inhibitor Staurosporine or its clinically relevant analogue UCN-01. British journal of cancer 94: 1436-1445, 2006.